Bandhan Healthcare Fund

Bandhan Healthcare Fund returned 9.68% in 2026 after a -1.58% decline in 2025, showing a mixed recent calendar-year record. The fund's XIRR and rolling return data are not available, so a like-for-like comparison against the category's SIP XIRR averages (12.19% for 1Y, 18.52% for 3Y) cannot be made. Investors should seek updated return data before drawing conclusions on relative performance.

The fund's risk profile appears exceptionally benign, with a maximum drawdown of just -0.087% that lasted 22 days and recovered in 95 days, and no drawdown events exceeding 10%. However, such shallow drawdowns are unusual for a sectoral equity fund and may reflect a limited measurement window rather than true long-term risk. Sector funds typically carry high concentration risk, so investors should not extrapolate this low volatility indefinitely.

Detailed holdings and sector allocation data are not provided, but as a healthcare sectoral fund the portfolio is concentrated in pharmaceuticals, hospitals, diagnostics, and related healthcare businesses. This single-sector mandate means the fund lacks diversification across industries by design. Investors should treat it as a satellite holding rather than a core portfolio allocation.

Without the fund's own XIRR figures, its standing versus category peers cannot be objectively assessed, though the category's strong long-term SIP XIRR averages (18-20% over 3-5 years) indicate a favorable peer environment. Calendar-year results of 9.68% in 2026 and -1.58% in 2025 suggest inconsistent year-to-year performance. Investors should compare updated XIRR data against the category averages once available.

This fund suits investors with high risk tolerance who already hold a diversified core portfolio and want tactical exposure to the healthcare sector. A time horizon of at least 5-7 years is advisable to ride out sector-specific cycles, as evidenced by the negative 2025 return. It is not appropriate as a first or primary equity fund for conservative investors.

• Very low observed drawdown risk, with a maximum drawdown of only -0.087% and zero drawdown events exceeding 10%
• Low expense ratio of 0.87% for a Direct plan, which helps preserve long-term returns
• Positive 2026 calendar-year return of 9.68%, indicating recovery from the prior year's decline

• XIRR and rolling return data are unavailable, making it impossible to verify performance against category averages of 12.19% (1Y) and 18.52% (3Y) SIP XIRR
• As a sectoral fund, it carries high concentration risk in healthcare, with a negative -1.58% return in 2025 highlighting sector cyclicality